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BACKGROUND: Cystectomy delay >90 days after a diagnosis of muscle-invasive bladder cancer (MIBC) adversely
affects pathologic stage and survival outcomes in patients who undergo primary surgery. After neoadjuvant chemo-
therapy (NAC), the impact of the timing of cystectomy delivery on these outcomes is uncertain. Poor communication
between urologic and medical oncologists can result in cystectomy delay after systemic treatment. The authors of
this report hypothesized that a delay in cystectomy delivery after NAC is associated with adverse survival outcomes.
METHODS: An eligible cohort of 153 patients with MIBC received NAC and underwent radical cystectomy between
1990 and 2007. At the authors’ institution, the genitourinary team strives to schedule patients for surgery at the time
of initial evaluation or after their first chemotherapy cycle. Clinicopathologic characteristics, including timing of cys-
tectomy, chemotherapy delivery, vital status, and reasons for excessive surgical delay, were analyzed retrospectively
using an institutional database. A Cox proportional regression model was used to test the association between the
timing of cystectomy delivery and survival. RESULTS: The median follow-up for all patients was 3.6 years. The median
time to cystectomy was 16.6 weeks and 6.9 weeks from the first and last day of NAC, respectively. In multivariate
analyses, the timing of cystectomy delivery from the termination of NAC did not significantly alter the risk of survival.
The most common reason for cystectomy delivery beyond 10 weeks (28 patients; 18%) was procedural scheduling.
CONCLUSIONS: Cystectomy delivery within 10 weeks after NAC did not compromise patient survival and, thus, pro-
vided a reasonable window for patient recovery and surgical intervention. Cancer 2012;118:44-53. VC 2011 American
Cancer Society.
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Historically, radical cystectomy has been the standard treatment for muscle-invasive bladder cancer (MIBC).1,2
Multiple studies have suggested that a delay in undergoing cystectomy is associated with adverse outcomes.3-9 Specifically,
a cystectomy delay>3 months after a diagnosis of MIBC has been associated with local tumor progression3 and worsened
progression-free survival,6 cancer-specific survival (CSS),5 and overall survival (OS).5
More recently, randomized trials and a meta-analysis have demonstrated a survival advantage for cisplatin-based
neoadjuvant chemotherapy (NAC) followed by radical cystectomy compared with cystectomy alone for the treatment of
MIBC.10,11 Outside of a clinical trial, the timing of cystectomy delivery after NAC can vary considerably, and a median
delay of 7 months after a diagnosis of MIBC has been reported by some large academic centers.12 The impact of cystec-
tomy delay after NAC on survival currently is uncertain. Previous studies demonstrating adverse outcomes with cystec-
tomy delay did not include patients who received NAC.3-5 A theoretical possibility of adverse outcomes exists for patients
who experience excessive cystectomy delay because of complications from NAC.13 However, delays also may result from
the administrative coordination of scheduling preparatory appointments, restaging evaluations, secondary opinions, and
DOI: 10.1002/cncr.26240, Received: December 20, 2010; Revised: April 6, 2011; Accepted: April 11, 2011, Published online May 19, 2011 in Wiley Online Library
(wileyonlinelibrary.com)
Corresponding author: Ajjai S. Alva, MD, Hematology/Oncology, Baylor College of Medicine, One Baylor Plaza, MS BCM 620, Houston, TX 77030; Fax: (713)
798-3342; alva@bcm.edu
1Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; 2Department of Urology, University of Michi-
gan, Ann Arbor, Michigan
44 Cancer January 1, 2012
Original Article
the actual surgical procedure. A lack of communication
between the urologist and medical oncologist can occur
during a 3-month course of systemic therapy, particularly
when both practice in different institutions.
In this study, we analyzed the impact of the timing
of cystectomy delivery after NAC on survival in patients
with MIBC in a collaborative, multidisciplinary cancer
program at an academic tertiary care center. We specifi-
cally sought to define a range of cystectomy delivery that
would compromise CSS or OS. We hypothesized that a
substantial delay in cystectomy delivery would result in
adverse survival outcomes.
MATERIALS AND METHODS
Patient Cohort
We retrospectively analyzed data from an institutional
review board-approved institutional database. Between
January 1990 and December 2007, 1012 consecutive
patients underwent radical cystectomy for high-risk blad-
der cancer at the University of Michigan, including 621
patients (61%) who had MIBC or clinical evidence of
extravesical tumor without metastatic disease. Of these
621 patients, 166 (27%) received NAC without subse-
quent adjuvant chemotherapy. From this cohort, 13
patients were excluded from the current analysis, includ-
ing 9 patients who had had pure nonurothelial histology,
2 patients who had a history of upper urinary tract cancer,
1 patient who withheld consent, and 1 patient who was
lost to follow-up. The remaining 153 patients formed our
study cohort.
Study Variables
Clinicopathologic parameters that were evaluated included
age, sex, Eastern Cooperative Oncology Group (ECOG)
performance status,14 American Society of Anesthesiolo-
gists (ASA) score,15 American Joint Committee on Cancer
TNM staging before NAC (clinical stage) and after cystec-
tomy (pathologic stage),16 histology and lymphovascular
invasion (LVI) at cystectomy, site of chemotherapy deliv-
ery (University of Michigan or other facility), chemothera-
peutic regimen, and dates of initiation and termination of
systemic treatment. Pathologically, organ-confined blad-
der cancer was defined as lymph node-negative (N0) dis-
ease with Ta, tumor in situ (Tis), T1, or T2 tumors.
Extravesical disease was defined as pathologic T3 or T4
tumors or Tany tumors with lymph node invasion (Nþ).
Clinical staging before NAC was based on histologic
evaluation at the time a patient underwent transurethral
resection of bladder tumor, examination under anesthesia,
and a metastatic survey, including plain radiograph or
computerized tomography (CT) studies of the chest and
axial imaging of the abdomen and pelvis with CT or mag-
netic resonance imaging. Bone scans were performed for
bulky tumors, bone-related symptoms, or elevated alka-
line phosphatase levels. Standard postoperative surveil-
lance was performed.17
Determinants for a substantial delay in undergoing
cystectomy (10 weeks after treatment termination) were
gleaned from the patient record. Reasons for delay were
identified as patient factors (adverse health status from
toxicity or comorbidities, patient preference, multiple
opinions) or physician/institution factors (extended NAC
on or off protocol, scheduling delay).
Chemotherapeutic Regimen
The 3 most commonly used NAC regimens were com-
bined paclitaxel, carboplatin, and gemcitibine (PCG)18
(paclitaxel 175 mg/m2 on Day 1, carboplatin at an area
under curve of 5 on Day 1, and gemcitabine 800 mg/m2
on Days 1 and 8 every 21 days for 3 cycles); combined
gemcitibine and cisplatin (GC)19,20 (gemcitabine 1000
mg/m2 on Days 1, 8, and 15 and cisplatin 70 mg/m2 on
Day 2 with cycles repeated every 28 days for 3 cycles); and
combined methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC)10 (methotrexate 30 mg/m2 on Days 1,
15, and 22; vinblastine 3 mg/m2 on Days 2, 15, and 22;
doxorubicin 30 mg/m2 on Day 2; and cisplatin 70 mg/m2
on Day 2 repeated every 28 days for 3 cycles). Thus, most
patients would be expected to receive NAC for 9 to 12
weeks. The ‘‘miscellaneous’’ group included regimens
other than PCG,MVAC, or GC.
Statistical Analysis
The interval from the first and last day of NAC to radical
cystectomy was used to calculate the time to cystectomy
delivery from the initiation and termination of NAC,
respectively. CSS was defined as the time from cystectomy
to the time of death from bladder cancer, and OS was
defined as the time from cystectomy to the time of death
from any cause. Patients were censored at the date of last
follow-up if they were alive or had died from causes unre-
lated to bladder cancer (CSS) or if they were alive (OS).
Log-rank tests were used to assess the unadjusted dif-
ference in survival probability among patient groups
stratified by clinical parameters. Hazard ratios (HRs) with
95% confidence intervals (CIs) were calculated using Cox
proportional hazards regression for this difference and for
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multivariate analyses. By using a process of forward selec-
tion of covariates, a step-wise Cox regression analysis was
used to generate multivariate models to determine the
odds of CSS and OS. Of the 11 variables that were consid-
ered for model selection, 8 variables for CSS and 9 varia-
bles for OS met criteria for inclusion based on their
univariate significance (P < .5) or their clinical relevance
with univariate P values < .3. Kaplan-Meier estimates
were used to create survival plots. Comparisons of timing
of cystectomy delivery by NAC regimen were performed
using the Wilcoxon rank-sum test or the Kruskal-Wallis
test. Comparisons of survival between NAC populations
(miscellaneous vs all others) were performed using the
log-rank test.
To identify correlations between the timing of cys-
tectomy delivery and survival, all possible delay points
were examined serially from the initiation and termina-
tion of NAC in weekly increments. Each assessment di-
vided the cohort into 2 subsets (those with cystectomy
delivery greater than the cutoff point and those with cys-
tectomy delivery less than or equal to the cutoff point).
Log-rank analyses then were used to detect any possible
difference in survival between the 2 subsets. A relevant
cutoff point was defined as one that resulted in a statisti-
cally significant survival difference between the 2 subsets
measured at that cutoff point and consistently at subse-
quent cutoff points. The 5% significance level was applied
to all tests and models. Analyses were performed using the
SAS statistical software package (SAS Institute, Inc., Cary,
NC).
RESULTS
Patient Demographics and Clinicopathologic
Parameters
Table 1 summarizes the cohort demographics of the 153
eligible patients. The mean age (64 years) and sex distri-
bution (73% men) were similar to other retrospective se-
ries and randomized trials of patients with MIBC
undergoing cystectomy.10,21 The median follow-up was
3.6 years from cystectomy. The ECOG performance sta-
tus before surgery was 0 in 94% of patients, reflecting
their suitability for cystectomy. In total, 76% of patients
received NAC at our home institution.
Patients typically received carboplatin-containing
(n ¼ 107; 69.5%) or cisplatin-containing (n ¼ 40;
26.1%) regimens, and only 6 patients (3.9%) did not
receive platinum-based therapy. Overall, 99 patients
(64.7%) received PCG, and 32 patients (21%) received
MVAC or GC, reflecting commitment to institutional
and national clinical trials,18,22 provider preference, or
compromised renal function. A fourth ‘‘miscellaneous’’
group consisted of 22 patients (14%) who received an
NAC regimen other than PCG, MVAC, or GC. Com-
pared with patients who received PCG, MVAC, or GC,
patients who received a miscellaneous regimen did not
differ significantly in age (P ¼ .72), ECOG performance
status (P ¼ .49), or ASA score (P ¼ .63). Fourteen of
those 22 patients (64%) were treated at our institution,
and 16 (73%) received a platinum drug as part of their
treatment regimen.
At the time of cystectomy, the ASA score largely was
2 (51%) or 3 (46%), which demonstrated the presence of
a significant number of coexisting comorbidities within
this well performing population. A pathologic complete
response to NAC (pT0) was observed in 24% of the
cohort, and another 12% demonstrated non-MIBC
(NMIBC) and no lymph node metastases. One hundred
forty-four of 153 patients (94%) underwent pelvic
lymphadenectomy, and 23% of patients had lymph node
invasion. LVI status was available in 147 (96%) patients.
We observed evidence of LVI in 27% of tumors, a rate
that was lower than the rates reported in cystectomy-alone
series.21,23
Timing of Cystectomy Delivery
The median time to cystectomy delivery from the initia-
tion of NAC was 16.6 weeks (range, 6.3-195.6 weeks;
25th and 75th percentiles, 13.9 weeks and 21.6 weeks,
respectively). The median time to cystectomy delivery
from the termination of NAC was 6.9 weeks (range, 1.7-
179.6 weeks; 25th and 75th percentiles, 5.3 weeks and
9.1 weeks, respectively). Pertinent variables were explored
to discern a potential association with cystectomy delivery
(Table 2). Advanced age (70 years), regimen type,
chemotherapy site, and advanced clinical stage did not
have an impact on the timing of cystectomy delivery.
Patients who had LVI, extravesical disease, or an incom-
plete treatment response did not have a longer time to cys-
tectomy compared with patients who did not have LVI,
patients who had organ-confined tumor, or patients who
achieved a complete pathologic response, respectively.
The association between survival and the timing of
cystectomy delivery from the termination of NAC is sum-
marized in Table 3 over Weeks 4 through 12. An analysis
of all evaluable time points at weekly intervals revealed no
difference in CSS or OS between those patients who were
treated at points longer than the delivery interval
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compared with those who were treated at points less than
or equal to the delivery interval. Log-rank analyses of
delivery time points <4 weeks and >12 weeks included
subsets of10% patients and, thus, were interpreted with
caution. A similar analysis of all evaluable time periods
(13-27 weeks) from the initiation of NAC to cystectomy
delivery also revealed no survival difference between
patients who were treated at points longer than the deliv-
ery interval compared with those who were treated at
points less than or equal to the delivery interval (data not
shown).
Cystectomy delivery occurred in 28 patients (18%)
10 weeks after the termination of NAC, reflecting the
population closest to the upper quintile with surgical
delay. The most common factor contributing to a pro-
longed time to surgery was ‘‘scheduling issues,’’ which
were observed in 11 patients (39%), including 7 patients
who were treated outside of our home institution. Adverse
health status because of patient comorbidity or toxicity
from NAC occurred in 3 patients (11%) and 4 patients
(14%), respectively. Elective delays in surgery related to
patient preference/multiple opinions (2 patients; 7%),
cystectomy refusal (6 patients; 21%), unknown factors (1
patient; 4%), or a combination of factors (1 patient; 4%)
occurred much less frequently.
Table 1. Cohort Demographics and Clinicopathologic
Parameters for the Entire Cohort (n¼152)
Parameter No. of Patients (%)
Age: MeanSE, y 64.260.86
Sex
Women 41 (27)
Men 112 (73)
NAC regimen
MVAC 12 (8)
GC 20 (13)
PCG 99 (65)
Miscellaneous 22 (14)
NAC site
UM Hospital 117 (76)
Outside hospital 36 (24)
Clinical stagea
T2N0M0 59 (39)
T3N0M0 57 (37)
T4N0M0 22 (14)
N1 15 (10)
T1N1M0 2 (1)
T2N1M0 4 (3)
T3N1M0 6 (4)
T4N1M0 3 (2)
ECOG performance
status at cystectomy
0 144 (94)
1 9 (6)
ASA score at cystectomyb
1 4 (3)
2 77 (51)
3 70 (46)
4 1 (1)
Histology at cystectomy
Urothelial 112 (73)
Mixed urothelial-small cell 2 (1)
Mixed urothelial-squamous cell 3 (2)
NAc 36 (23)
Lymphovascular invasion
at cystectomyd
Present 39 (27)
Absent 108 (73)
Pathologic stage
Tumor classification
T0 36 (24)
Ta 2 (2)
Tis 14 (10)
T1 6 (4)
T2 23 (15)
T3 51 (33)
T4 21 (14)
Lymph node status
N0 109 (71)
N1 35 (23)
TaN1 1 (1)
TisN1 2 (1)
(Continued)
Table 1. (Continued)
Parameter No. of Patients (%)
T1N1 1 (1)
T2N1 2 (1)
T3N1 19 (12)
T4N1 10 (7)
Nx 9 (6)
Overall pathologic stage
Organ confined 75 (49)
Extravesical 78 (51)
Marital status
Married 115 (75)
Not married 38 (25)
Year of surgery
2001-2009 129 (84)
1990-2000 24 (16)
Abbreviations: ASA, American Society of Anesthesiologists physical status
scale; ECOG, Eastern Cooperative Oncology Group; GC, gemcitabine and
cisplatin; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; NA,
not applicable; NAC, neoadjuvant chemotherapy; PCG, paclitaxel, carbo-
platin, and gemcitabine; SE, standard error; Tis, tumor in situ; UM, Univer-
sity of Michigan.
a Reflects the clinical stage before NAC.
b The ASA score was unknown in 1 patient.
c Reflects a pathologic complete response.
d Lymphovascular invasion status was not available for 7 patients.
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Variables Impacting OS
The median OS was 2.6 years, and the 2-year and 5-year
survival rates were 57% and 38%, respectively. At the
time of the current report, the median CSS had not been
reached, and the 2-year and 5-year CSS rates were 60%
and 52%, respectively. In total, 2 patients (1.3%) died in
the perioperative period within 30 days of cystectomy.
Table 4 summarizes the association between the study var-
iables and CSS. Pathologic stage, LVI, NAC regimen, and
year of surgery year were all associated with CSS in univar-
iate analysis. Table 5 summarizes the association between
study variables and OS. Pathologic stage, LVI, NAC regi-
men, and ASA score were associated with OS in univariate
analysis. Although the type of chemotherapy regimen was
associated statistically with CSS and OS in univariate
analyses, there certainly were analytic limitations because
of the small numbers of patients receiving specific
regimens, particularly in the MVAC group. Secondary
analyses attributed the survival difference to the superior-
ity of established regimens (GC and PCG) over the
Table 2. Timing of Radical Cystectomy Delivery From the Last Day of Neoadjuvant
Chemotherapy Stratified by Clinicopathologic Parameters
Timing of Radical
Cystectomy
Delivery After
NAC, wk
Variable No. of Patients (%) Mean6SE Median Pa
Age, y
<70 97 (65) 8.901.81 7.14 .09
‡70 52 (35) 12.692.80 6.71
NAC regimen
MVAC 10 (8) 8.531.43 6.64 .67
GC 20 (13) 6.990.88 6.36
PCG 99 (66) 11.432.28 7.14
Miscellaneous 20 (13) 8.290.91 6.50
NAC site
UM Hospital 114 (77) 10.841.99 6.86 .99
Outside hospital 35 (23) 8.190.76 6.14
Clinical tumor classificationb
£T2 63 (42) 13.543.53 6.71 .66
‡T3 86 (58) 7.790.49 6.93
Lymphovascular invasion
at cystectomy
Present 38 (27) 6.910.41 6.50 .46
Absent 107 (73) 11.402.12 6.86
Pathologic stage
Organ confined 75 (50) 8.420.64 7.00 .40
Extravesical 74 (50) 12.043.01 6.71
Response to NAC
Complete response: pT0 36 (24) 13.234.93 6.21 .39
Incomplete response: Non-pT0 113 (76) 9.261.28 6.86
Marital status
Married 113 (76) 10.141.98 6.71 .22
Not married 36 (24) 10.461.28 7.43
Year of surgery
2001-2009 129 (87) 10.541.76 6.71 .73
1990-2000 20 (13) 8.170.92 7.07
Abbreviations: GC, gemcitabine and cisplatin; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; NAC, neo-
adjuvant chemotherapy; PCG, paclitaxel, carboplatin, and gemcitabine; SE, standard error; UM, University of
Michigan.
a Based on the median time to cystectomy delivery.
b Reflects the clinical stage before NAC.
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‘‘miscellaneous’’ group with respective HRs of 0.24 (95%
CI, 0.10-0.61) and 0.45 (95% CI, 0.27-0.77). Multivari-
ate models (Tables 4 and 5) demonstrated that pathologic
stage and year of surgery were the strongest predictors of
CSS, whereas pathologic stage was the strongest predictor
of OS. The timing of cystectomy delivery after NAC as a
continuous variable did not have an impact on CSS (HR,
0.97; 95% CI, 0.92-1.03; P ¼ .32) or OS (HR, 0.97;
95%CI, 0.93-1.01; P¼ .24).
Optimal survival was observed among the patients
who achieved a complete pathologic response (pT0), with
2-year and 5-year OS rates of 80% and 63%, respectively
(Fig. 1); whereas the collective population with residual
disease had 2-year and 5-year OS rates of 49% and 29%,
respectively. Patients who had residual nonmuscle-inva-
sive disease had more favorable survival rates compared
with patients who had residual muscle-invasive and extra-
vesical disease (P ¼ .02) (Fig. 2). The 2-year and 5-year
OS rates were 68% and 53%, respectively, for patients
with lymph node negative NMIBC and 44% and 24%,
respectively, for the combined population of patients with
muscle-invasive and extravesical disease. There was no sig-
nificant difference in the survival of patients with pT0N0
disease and those with pathologic NMIBC (P¼ .33).
DISCUSSION
The current data demonstrate the feasibility of efficient
delivery of cystectomy after NAC for MIBC in a multidis-
ciplinary group practice. The median time to cystectomy
from the termination of NAC was<7 weeks, and 80% of
the study cohort underwent cystectomy by 10 weeks. Age
did not have an impact on the timing of surgery. Patients
aged >70 years (34% of the cohort) underwent cystec-
tomy at a median of 6.7 weeks after the completion of
treatment and enjoyed an OS similar to that of younger
patients (aged <70 years). Systemic treatment at an out-
side institution did not delay cystectomy delivery or com-
promise survival. Furthermore, the timing of cystectomy
delivery did not appear to contribute to local disease pro-
gression, in that patients with higher pathologic stage
tumors had a time to cystectomy similar to that of patients
with organ-confined disease. Likewise, an incomplete
pathologic response could not be attributed to prolonged
time to cystectomy delivery. Despite the use of multiple
regimens in this study group, the timing of cystectomy
delivery after NAC across the various therapies was simi-
lar, with a median that ranged from 6.4 weeks to 7.1
weeks.
The majority of our patients (65%) received neoad-
juvant PCG in keeping with ongoing institutional and
national clinical trials during the study period.18,22 These
trials certainly impacted general practice patterns at our
institution, because several patients received this regimen
off protocol. Consequently, only 21% of the cohort
received a standard cisplatin-based regimen. Moreover,
14% received alternative regimens generally because of
individual patient comorbidity. The resultant survival
outcomes in this cohort may be a reflection of the pre-
dominant use of carboplatin instead of cisplatin-based
regimens. The 2-year and 5-year survival rates of 57% and
38%, respectively, were lower than expected when consid-
ering the survival rates reported from randomized trials
that used primarily cisplatin-based neoadjuvant combina-
tions before local therapy. For example, data from the
Advanced Bladder Cancer Meta-Analysis Collaborative
comparing randomized NAC and cystectomy with cystec-
tomy alone suggested 2-year and 5-year OS rates of
Table 3. Patient Survival Stratified by Cystectomy Delivery After Termination of Neoadjuvant Chemotherapy (n¼149)a
No. of Patients Cancer-Specific Survival Overall Survival
Weeks to
Cystectomy
£Delivery
Time Point
>Delivery
Time Point
HR (95% CI) Log-Rank P HR (95% CI) Log-Rank P
4 15 134 1.24 (0.53-2.88) .62 1.77 (0.77-4.09) .17
5 32 117 0.86 (0.48-1.53) .60 0.99 (0.58-1.67) .96
6 55 94 0.80 (0.49-1.32) .38 1.08 (0.69-1.69) .74
7 81 68 0.86 (0.52-1.41) .54 1.05 (0.68-1.62) .83
8 103 46 1.07 (0.63-1.84) .80 1.21 (0.76-1.91) .42
9 111 38 1.29 (0.74-2.24) .38 1.38 (0.86-2.22) .19
10 121 28 1.22 (0.65-2.28) .54 1.50 (0.90-2.52) .12
11 127 22 1.01 (0.48-2.12) .98 1.35 (0.74-2.44) .32
12 131 18 0.66 (0.27-1.65) .37 1.10 (0.57-2.13) .78
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Data on the end date for chemotherapy were unavailable for 4 patients.
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approximately 68% and 48%, respectively.11 Patients
who received alternative regimens in the miscellaneous
category in our cohort had survival rates that were inferior
to those achieved by patients who received either PCG or
GC, although selection bias and case mix likely influenced
this result.
Pathologic staging at the time of cystectomy was a
strong predictor of survival, and patients who had
Table 4. Cancer-Specific Mortality Stratified by Clinicopathologic Parameters
No. (%) Univariate
Analysis
Multivariate
Analysis
Variable Cancer-Specific
Deaths
Alive or Dead
of Other Causes
HR [95% CI] Log-Rank P HR [95% CI] P
Age, ya
<70 44 (44) 56 (56) 1.02 [0.61-1.72] .93 NA NA
‡70 21 (40) 32 (60)
NAC regimen
MVAC 7 (58) 5 (42) Reference .01 Reference .34
GC 5 (25) 15 (75) 0.40 [0.13-1.25] 0.84 [0.20-3.51]
PCG 39 (39) 60 (60) 0.64 [0.29-1.44] 0.96 [0.32-2.87]
Miscellaneous 14 (64) 8 (36) 1.50 [0.60-3.72] 1.85 [0.60-5.75]
NAC site
UM Hospital 47 (41) 69 (59) 0.72 [0.42-1.24] .23 0.86 [0.46-1.61] .64
Outside hospital 18 (49) 19 (51)
Clinical tumor
classification
before NAC
£T2 22 (34) 43 (66) 1.56 [0.93-2.60] .09 1.32 [0.71-2.46] .38
‡T3 43 (49) 45 (51)
ECOG performance
status at
cystectomya
0 61 (42) 83 (58) 0.87 [0.31-0.39] .78 NA NA
1 4 (44) 5 (56)
ASA score at
cystectomy
1, 2 31 (38) 50 (62) 1.46 [0.89-2.38] .13 1.50 [0.87-2.58] .15
3, 4 34 (48) 37 (52)
Lymphovascular
invasion at
cystectomy
Present 27 (69) 12 (31) 2.94 [1.75-5] <.0001 1.49 [0.79-2.86] .21
Absent 33 (31) 75 (69)
Pathologic stage
Extravesical 50 (64) 28 (36) 4.55 [2.5-8.33] <.0001 4.76 [2.27-10.0] <.0001
Organ confined 15 (20) 60 (80)
Marital statusa
Married 50 (43) 65 (57) 0.93 0.52-1.66] .81 NA NA
Not married 15 (39) 23 (61)
Year of surgery
1990-2000 15 (63) 9 (37) 1.92 [1.06-3.45] .03 2.63 [1.10-6.25] .03
2001-2009 50 (39) 79 (61)
Cystectomy delivery from
termination of NAC
0.97 [0.92-1.03] .32
Abbreviations: ASA, American Society of Anesthesiologists physical status scale; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GC,
gemcitabine and cisplatin; HR, hazard ratio; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; NA, not applicable; NAC, neoadjuvant chemotherapy;
PCG, paclitaxel, carboplatin, and gemcitabine; UM, University of Michigan.
a Not included in multivariate analysis.
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extravesical tumors had nearly 5-fold and 3-fold increases
in the risk of death from bladder cancer or from any cause,
respectively, compared with patients who had organ-con-
fined tumors. Surgery year was an independent predictor
of CSS. Within the cohort, 24% had a complete patho-
logic response, and another 12% had residual NMIBC,
and both were associated with superior survival outcomes
compared with patients who had muscle-invasive or extra-
vesical disease.10 The frequency of pT0 after NAC varies
in published series based on the regimen and study design
Table 5. All-Cause Mortality Stratified by Clinicopathologic Parameters
No. (%) Univariate Analysis Multivariate Analysis
Variable Dead Alive HR [95% CI] Log-Rank P HR [95% CI] P
Age, y
<70 54 (54) 46 (46) 0.75 [0.48-1.16] .19 1.5 [0.9-2.57] .12
‡70 33 (62) 20 (38)
NAC regimen
MVAC 8 (67) 4 (33) Reference .004 Reference 0.43
GC 6 (30) 14 (70) 0.47 [0.16-1.40] 0.75 [0.20-2.78]
PCG 53 (54) 46 (46) 0.83 [0.39-1.76] 0.93 [0.33-2.56]
Miscellaneous 20 (91) 2 (9) 1.73 [0.75-3.99] 1.51 [0.52-4.43]
NAC site
UM Hospital 63 (54) 53 (46) 0.70 [0.43-1.12] .13 1.32 [0.76-2.25] .34
Outside hospital 24 (65) 13 (35)
Clinical tumor
classification
before NAC
£T2 32 (49) 33 (51) 0.73 [0.47-1.13] .15 1.11 [0.65-1.9] .7
‡T3 55 (63) 33 (37)
ECOG performance
status at
cystectomya
0 83 (58) 61 (42) 1.19 [0.43-3.25] .74 NA NA
1 4 (44) 5 (56)
ASA score at
cystectomy
1, 2 42 (52) 39 (48) 1.63 [1.05-2.5] .03 0.63 [0.39-1.05] .64
3, 4 45 (63) 26 (37)
Lymphovascular
invasion at
cystectomy
Absent 52 (48) 56 (52) 0.45 [0.28-0.71] .0005 1.32 [0.74-2.36] .34
Present 29 (74) 10 (26)
Pathologic stage
Organ confined 28 (37) 47 (63) 3.33 [2.04-5.26] <.0001 3.0 [1.65-5.42] .0003
Extravesical 59 (76) 19 (24)
Marital statusa
Married 65 (57) 50 (43) 0.91 [0.56-1.48] .71 NA NA
Not married 22 (58) 16 (42)
Year of surgery
2001-2009 66 (51) 63 (49) 0.62 [0.36-1.05] .07 2.17 [0.98-4.80] .06
1990-2000 21 (87) 3 (13)
Cystectomy delivery from
termination of NAC
0.97 [0.93-1.01] .24
Abbreviations: ASA, American Society of Anesthesiologists physical status scale; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GC,
gemcitabine and cisplatin; HR, hazard ratio; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; NA, not available; NAC, neoadjuvant chemotherapy;
PCG, paclitaxel, carboplatin, and gemcitabine; UM, University of Michigan.
a Not included in multivariate analysis.
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(7%-28% in single-center, retrospective studies using
MVAC or GC12,24; 18% in a multicenter phase 2 study
using PCG22; and 38% in a multicenter, cooperative
group, randomized controlled trial using MVAC10). The
pT0 rate of 24% in the current series is certainly a reflec-
tion of ‘‘real world’’ practice with the administration of dif-
ferent systemic regimens to a population of patients who
had a variety of social circumstances and comorbidities.
Although our population included high-performing
patients, nearly 50% of the study cohort had substantial
medical conditions, as evidenced by ASA scores of 3 or 4.
Our inclusion of these patient categories reflects the aggres-
siveness with which our group delivers NAC. Finally, an
important observation was the similar 2-year and 5-year
survival of patients with pT0 and residual NMIBC, sug-
gesting that a finding of Ta, Tis, or T1 at cystectomy is of
great importance to this population. Consequently, the
presence of pathologic NMIBC after NAC is a relevant
endpoint that should be considered in NAC trials.
An assessment of the patterns of survival stratified
by the timing of cystectomy suggested similar survival
when cystectomy was delivered within 4 to 12 weeks after
the termination of chemotherapy. Although we did not
observe a survival disadvantage in the weeks before or after
this time period, these analyses had small cohorts of
patients; thus, the results must be interpreted with caution.
The patient numbers in the analyses up to and including
10 weeks after NAC termination were more robust, per-
mitting greater confidence in deeming this a safe window
for cystectomy delivery after NAC. Although we strive to
deliver cystectomy as expeditiously as possible after NAC,
there is potential benefit in permitting some patients an
additional 1 to 3 weeks to recover from systemic therapy.
In that context, we can be more confident that a brief delay
up to 10 weeks after NAC is unlikely to compromise CSS
or OS. The data evaluating survival patterns from the ini-
tiation of chemotherapy resulted in similar conclusions.
Delays in surgery beyond 10 weeks after NAC ter-
mination certainly are possible because of complications
from systemic treatment, patient indecision, and/or coordi-
nation of care between medical oncology and urology.
Within our study population, the 28 patients (18%) who
underwent cystectomy at or beyond 10 weeks generally had
delays because of procedural scheduling. Adverse health sta-
tus related to patient comorbidity or NAC toxicity also was
an important cause of surgical delay, whereas delays caused
by patient preference or multiple opinions were infrequent.
It is worthwhile to note that scheduling issues occurred dis-
proportionately in those who were receiving NAC outside
of our institution, emphasizing the need for good commu-
nication and planning. Still, we did not observe a survival
disadvantage for patients who were treated outside our facil-
ity; thus, treatment away from the home institution should
not dissuade the use of NAC before cystectomy.
Although the findings from this study are interest-
ing, they are limited by the retrospective nature of the
study and because the data were compiled from a single
center with potentially unique patient referral and practice
patterns. We specifically identified patients who received
Figure 1. Overall survival stratified according to pathologic
complete response (pT0) versus incomplete response.
Figure 2. Overall survival stratified according to pathologic
stage. pT indicates pathologic complete response; Tis, tumor
in situ.
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NAC and were able to undergo radical cystectomy,
because our intent was to evaluate the timing of cystec-
tomy delivery. Consequently, we did not collect data on
patients who initiated NAC but did not undergo cystec-
tomy because of either treatment-related toxicity or death,
patient refusal, or disease progression.
In conclusion, concerns regarding the use of NAC
have been attributed in part to apprehension over the tim-
ing of cystectomy delivery after systemic treatment. Our
data demonstrate the feasibility of timely cystectomy
when a neoadjuvant strategy is used to treat MIBC, even
when therapies are administered at different institutions.
It is noteworthy that, should unanticipated actions delay
surgery, then cystectomy delivery up to a period of 10
weeks after the termination of NAC is unlikely to com-
promise patient survival. Active communication between
treating physicians facilitates surgical scheduling and min-
imizes treatment delays and patient uncertainty.
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